Vapendavir is under clinical development by Altesa Biosciences and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Vapendavir’s likelihood of approval (LoA) and phase transition for Rhinovirus Infections took place on 01 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vapendavir Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Vapendavir (BTA-798) is under development for the treatment of rhinovirus infections. Vapendavir is administered through oral route. It acts by targeting the capsid protein. It was under development for the treatment of rhinovirus infections in moderate to severe asthmatics.
Altesa Biosciences overview
Quick View Vapendavir LOA Data
|Highest Development Stage|